Genomic PD-1 checkpoint disruption in the context of allogeneic CAR-T cell therapy may provide a compelling option for treating B lymphoid malignancies.
over 1 year ago
Journal • CAR T-Cell Therapy
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
After serially receiving lymphodepletion therapy with cyclophosphamide (60mg/kg/day for 2 days) and fludarabine (25mg/m2/day for 5 days), pts receive a single dose infusion of CB-010 and are followed for safety and efficacy. Dose escalation of CB-010 is ongoing, and patients are being enrolled in cohort 2 to receive a single dose of 80 million CAR-T cells. The ANTLER Phase 1 trial is registered on clinicaltrials.gov (NCT04637763).
2 years ago
Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker